NCT05345990 - Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Chronic Hepatitis B

Interventions

DRUG

Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)

"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"

Trial Locations (1)

30625

Hannover Medical School, Department for Gastroenterology, Hepatology and Endocrinology, Hanover